Stage 4 Pancreatic Cancer: Symptoms, Treatment and Survival Outlook

A diagnosis of stage 4 pancreatic cancer can raise difficult questions. Has the cancer spread? Which treatments are still available? What does the survival rate really mean?

Stage 4 pancreatic cancer means the disease has spread beyond the pancreas to distant parts of the body. The liver, lungs, and the lining of the abdomen are among the possible sites. Although this stage is serious and usually cannot be removed with surgery, treatment may help control the cancer, relieve symptoms, and give some people more time.

Treatment has also continued to evolve. Chemotherapy remains an important option, while molecular testing can identify selected patients who may benefit from targeted treatments. In August 2026, the FDA approved daraxonrasib for certain adults with metastatic pancreatic adenocarcinoma, adding a new option in a specific treatment setting.

This article covers what stage 4 means, how the disease is diagnosed, which treatments may be considered, and how to interpret survival statistics without treating them as an individual prediction.

1. What Does Stage 4 Pancreatic Cancer Mean?

Doctors use cancer staging to describe how far a cancer has grown or spread. Pancreatic cancer is commonly staged using the TNM system, which considers the primary tumor (T), nearby lymph nodes (N), and distant metastasis (M).

In stage IV pancreatic cancer, the tumor may be any size, but it has spread to distant parts of the body. This is classified as M1 disease.

For example, if pancreatic cancer spreads to the liver, the cancer cells found in the liver are still pancreatic cancer cells. It is called metastatic pancreatic cancer, not primary liver cancer.

Stage 4 versus locally advanced pancreatic cancer

These terms describe different situations:

• Locally advanced disease: The cancer has grown into nearby structures or major blood vessels but has not spread to distant organs.
• Metastatic or stage 4 disease: Cancer has spread to distant organs or sites, such as the liver, lungs, or peritoneal cavity.

This distinction matters because treatment planning is different. Surgery may be considered in selected non-metastatic cases, but metastatic pancreatic cancer is generally treated with systemic therapy rather than surgery to remove the cancer.

Which type of pancreatic cancer does this article cover?

Most pancreatic cancers are exocrine cancers, and pancreatic ductal adenocarcinoma (PDAC) is the most common type.

Pancreatic neuroendocrine tumors (PNETs) are less common and have different biology, treatment approaches, and survival patterns. Their statistics should not be mixed with those for pancreatic adenocarcinoma.

The treatment and survival discussion below focuses mainly on metastatic pancreatic adenocarcinoma.

2. Where Does Stage 4 Pancreatic Cancer Spread?

Pancreatic cancer cells can travel through the bloodstream or lymphatic system and form tumors in other parts of the body.

Common metastatic sites include:

Liver

The liver is one of the most frequent sites of pancreatic cancer spread. Liver involvement may contribute to jaundice, abdominal discomfort, appetite changes, or abnormal liver blood tests. Some people have no obvious liver-related symptoms. For more information about possible liver-related discomfort, read what liver pain can feel like.

Lungs

When pancreatic cancer spreads to the lungs, symptoms may include a persistent cough, shortness of breath, or chest discomfort. However, some lung metastases are found on scans before they cause symptoms.

Peritoneum

The peritoneum is the thin lining inside the abdomen. Cancer spread to this lining can cause irritation and fluid accumulation, known as ascites.

Ascites may lead to abdominal swelling, a feeling of fullness, discomfort, and reduced appetite.

Other sites

Less commonly, pancreatic cancer can spread to bones or other distant tissues. The location and extent of spread help doctors assess symptoms and choose an appropriate treatment plan.

3. Stage 4 Pancreatic Cancer Symptoms

Symptoms vary from person to person. Some are related to the original pancreatic tumor, while others develop because the cancer has spread.

Common symptoms include:

• Abdominal pain: Pain in the upper abdomen may extend into the back.
• Unexplained weight loss: Reduced appetite, changes in digestion, and the effects of cancer can contribute.
• Jaundice: Yellowing of the skin or whites of the eyes may occur when a tumor blocks the bile duct.
• Dark urine and pale stools: These changes can occur when bile flow is obstructed.
• Fatigue: Cancer and its treatment can both contribute to persistent tiredness.
• Nausea and vomiting: These may result from the disease, treatment, or digestive complications.
• Blood clots: Pancreatic cancer can increase the risk of abnormal clot formation.
• Abdominal swelling: Fluid accumulation in the abdomen may cause bloating or discomfort.

Not everyone experiences all these symptoms. New or worsening symptoms should be discussed with the treating medical team, especially severe pain, persistent vomiting, jaundice, breathing difficulty, or signs of a blood clot.

4. How Is Stage 4 Pancreatic Cancer Diagnosed?

Diagnosis involves confirming the cancer and determining whether it has spread.

Doctors may use several tests together.

Imaging tests

• CT scan: Often used to examine the pancreas, liver, lungs, and other areas for possible spread.
• MRI: Can provide additional detail about the pancreas, liver, and surrounding structures.
• PET scan: May be used in selected situations to assess suspicious areas of cancer activity.
• Endoscopic ultrasound (EUS): Uses an ultrasound device attached to an endoscope to examine the pancreas and nearby structures.

The choice of imaging depends on the clinical situation and the information doctors need.

Biopsy and pathology

A biopsy collects a tissue sample for examination under a microscope. It helps confirm the cancer type and may provide material for additional molecular testing.

Blood tests and CA 19-9

Blood tests may include liver function tests and the tumor marker CA 19-9.

CA 19-9 can help doctors follow disease activity in some patients, but it cannot independently confirm pancreatic cancer. It may also be elevated in certain non-cancerous conditions, and not every person with pancreatic cancer has an elevated result.

Molecular and genetic testing

Molecular testing examines tumor tissue or other samples for specific genetic changes that may affect treatment choices.

Doctors may also recommend inherited genetic testing. Tumor testing and inherited genetic testing answer different questions, and both may be relevant when planning care.

5. Stage 4 Pancreatic Cancer Treatment Options

Treatment depends on several factors, including the cancer’s molecular features, previous treatment, general health, symptoms, and ability to tolerate therapy.

The main aim is usually to control the disease, extend life where possible, and maintain quality of life.

Chemotherapy

Chemotherapy remains a major treatment option for metastatic pancreatic adenocarcinoma.

Common combination regimens include:

• FOLFIRINOX: A combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin.
• Gemcitabine plus nab-paclitaxel: A combination used in metastatic pancreatic cancer.
• NALIRIFOX: A regimen combining liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin.

These treatments are not suitable for everyone. The oncology team considers physical fitness, organ function, existing health conditions, previous treatment, and expected side effects before selecting a regimen.

For some people, a less intensive treatment approach or supportive care may be more appropriate.

Targeted therapy and biomarker testing

Some pancreatic tumors contain genetic changes that can help guide treatment.

For example:

• BRCA1 and BRCA2: Certain patients with these inherited or tumor-related changes may benefit from platinum-based chemotherapy and, in selected settings, PARP inhibitor maintenance treatment.
• MSI-H or dMMR: These uncommon findings may make immunotherapy relevant for selected patients.
• NTRK gene fusions: Rare tumors with these alterations may qualify for a TRK-targeted medicine.

The presence of a biomarker does not automatically mean a treatment will work. The specific alteration, approved indication, previous treatment, and clinical circumstances all matter.

Daraxonrasib: A newly FDA-approved treatment

An important treatment development arrived on August 26, 2026, when the U.S. FDA approved daraxonrasib (RASONQUE), a RAS GTPase inhibitor, for certain adults with metastatic pancreatic adenocarcinoma.

The approved indication covers adults who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.

The approval was supported by the Phase 3 RASolute 302 trial. In the overall study population:

• Median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy.
• Median progression-free survival was 7.2 months versus 3.6 months.
• The objective response rate was 30% versus 11%.

These are results from the trial population, not a prediction of how long an individual patient will live. The trial enrolled people with metastatic pancreatic adenocarcinoma in a defined treatment setting, so its findings should not be applied to every person with pancreatic cancer.

Daraxonrasib also has important safety warnings, including skin and soft-tissue toxicity, mouth and oral problems, diarrhea, gastrointestinal perforation, and interstitial lung disease or pneumonitis.

For a closer explanation of its mechanism, trial results, approval, and safety profile, read our guide to daraxonrasib for pancreatic cancer.

Immunotherapy

Immunotherapy is not a routine treatment for every pancreatic cancer patient. It may be considered when testing identifies particular biomarkers, such as MSI-H or dMMR, that make the tumor more likely to respond.

The treating oncologist must interpret the test results and determine whether an approved treatment or clinical trial is appropriate.

Radiation and procedures for symptom relief

Radiation therapy is not a cure for widespread metastatic disease, but it may be considered in selected cases to relieve pain or manage a specific local problem.

Procedures may also be used to relieve complications. For example, a stent can help restore bile flow when a tumor blocks the bile duct.

6. Stage 4 Pancreatic Cancer Survival Rate

Survival statistics can help explain the overall outlook, but they cannot tell exactly what will happen to one person.

According to the U.S. National Cancer Institute’s SEER data for 2016–2022, the five-year relative survival rate for pancreatic cancer classified as distant stage was 3.4%.

This means that, at a population level, people in this group were estimated to be about 3.4% as likely to be alive five years after diagnosis as comparable people in the general population.

There is an important distinction: SEER uses a combined summary-stage classification of localized, regional, and distant disease. Its distant-stage category is not exactly the same as the AJCC stage IV classification used in an individual patient’s medical record.

The figure also includes pancreatic cancer cases across types. It should not be presented as a precise survival estimate for every patient with stage IV pancreatic ductal adenocarcinoma.

What affects survival?

Several factors can influence an individual’s outlook:

• The exact type and biology of the tumor.
• Where the cancer has spread and how much disease is present.
• General health and ability to carry out daily activities.
• Whether the tumor has molecular features that open additional treatment options.
• Response to treatment.
• Whether treatment side effects can be managed safely.

A survival statistic describes a large group of people diagnosed in earlier years. It cannot account for every new treatment or predict an individual’s response.

7. Complications of Stage 4 Pancreatic Cancer

Advanced pancreatic cancer can affect digestion, nutrition, liver function, and other parts of the body.

Bile duct obstruction and jaundice

A tumor near the bile duct may block the flow of bile. This can cause jaundice, dark urine, pale stools, and itching. A stent may be used to help keep the duct open.

Weight loss and digestive problems

The pancreas produces enzymes needed to digest food. When pancreatic function is affected, some people develop pancreatic exocrine insufficiency.

This can cause greasy stools, bloating, diarrhea, and difficulty maintaining weight. Doctors may prescribe pancreatic enzyme replacement therapy when appropriate.

Pain

Pain may arise from the primary tumor, nearby nerves, or metastatic disease. Treatment can include medication, specialist pain management, and selected procedures.

Ascites

Cancer involving the peritoneum may lead to fluid accumulation in the abdomen. Depending on the cause and symptoms, doctors may use drainage procedures and other supportive measures.

Blood clots

Pancreatic cancer increases the risk of venous blood clots. Sudden leg swelling, pain, chest pain, or shortness of breath needs prompt medical assessment.

8. Palliative Care and Quality of Life

Palliative care focuses on relieving symptoms and supporting physical, emotional, and practical needs. It can be provided alongside cancer treatment; it does not mean that active treatment has stopped.

Support may include:

• Pain and nausea management.
• Help with appetite, nutrition, and digestion.
• Support for fatigue and sleep problems.
• Emotional and psychological care.
• Guidance for family members and caregivers.

Hospice care is different. It focuses on comfort near the end of life when the person and care team decide that this approach best fits their needs and goals.

Early discussion of supportive care can help patients and families understand available services and make informed decisions.

9. Clinical Trials and Emerging Research

Researchers are studying ways to target pancreatic cancer biology, address treatment resistance, and improve outcomes.

Areas of interest include:

• RAS-targeted medicines.
• Biomarker-guided treatment combinations.
• New approaches to immunotherapy.
• Treatments designed to overcome resistance to existing medicines.

A clinical trial may be an option for some people, depending on the cancer type, previous treatment, molecular test results, location, and eligibility criteria.

An investigational treatment should not be described as an established cure. Patients can ask their oncology team whether an appropriate trial is available and what its possible benefits and risks are.

Frequently Asked Questions

Is stage 4 pancreatic cancer curable? +

Stage 4 pancreatic cancer is generally not considered curable with current standard treatment. However, treatment may slow the disease, relieve symptoms, and help some people live longer.

Where does pancreatic cancer spread first? +

The liver is a common site of distant spread. Pancreatic cancer can also spread to the lungs and the peritoneal cavity. The pattern varies from person to person.

What are the most common symptoms of stage 4 pancreatic cancer? +

Symptoms may include abdominal or back pain, weight loss, jaundice, fatigue, appetite loss, nausea, and abdominal swelling. Symptoms depend partly on where the cancer has spread.

How long can someone live with stage 4 pancreatic cancer? +

There is no single timeline. Survival depends on tumor biology, general health, treatment options, and response to therapy. Population statistics cannot predict an individual’s lifespan.

Can chemotherapy help stage 4 pancreatic cancer? +

Yes. Chemotherapy is an important treatment option for many people with metastatic pancreatic adenocarcinoma. The specific regimen depends on fitness, previous treatment, and other clinical factors.

Does stage 4 pancreatic cancer always cause pain? +

No. Some people experience significant pain, while others have mild discomfort or no pain. Pain can often be managed with help from the oncology and palliative care teams.

What happens when pancreatic cancer spreads to the liver? +

Liver metastases may cause discomfort, changes in liver blood tests, jaundice, or other symptoms. Some people have no symptoms from liver involvement. Treatment is planned according to the overall disease and the person’s health.

Is stage 4 pancreatic cancer always terminal? +

Stage 4 pancreatic cancer is a life-threatening advanced disease, but the course varies. Treatment may control the cancer for a period and improve symptoms. The treating team can explain what the diagnosis means in an individual case.

Bottom Line

Stage 4 pancreatic cancer means the disease has spread beyond the pancreas to distant parts of the body. It is a serious diagnosis, but treatment decisions are not limited to one approach.

Chemotherapy, biomarker-guided treatment, selected targeted medicines, clinical trials, and palliative care may all have a role. The best plan depends on the cancer’s biology, previous treatment, overall health, and the patient’s goals.

Survival statistics provide context, not a personal deadline. A discussion with an experienced oncology team can help clarify the available options and what matters most for each individual.

References

1. National Cancer Institute. Pancreatic Cancer Stages.
2. National Cancer Institute. Pancreatic Cancer Testing and Diagnosis.
3. National Cancer Institute. Pancreatic Cancer Treatment.
4. National Cancer Institute. Pancreatic Cancer Survival Rates and Prognosis.
5. National Cancer Institute SEER Program. Cancer Stat Facts: Pancreatic Cancer.
6. U.S. Food and Drug Administration. FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma.
7. DailyMed. RASONQUE (daraxonrasib) Prescribing Information.
8. National Cancer Institute. Pancreatic Cancer Treatment PDQ.